INTELLIA THERAPEUTICS, INC. (NTLA) Quick Ratio
- Quick ratio · latest quarter: Value 5.61×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 5.61× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $445.08M ÷ $79.39M ≈ 5.61× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 445.08M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 79.39M USD | Liabilities, Current |
| Cash and equivalents | 106.13M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 331.63M USD | Marketable Securities, Current |
| Customer receivables | 7.32M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $445.08M | $79.39M | $106.13M | $331.63M | $7.32M | (m) | 5.61× |
| 2026-03-31 | $385.12M | $76.44M | $134.70M | $241.29M | $9.13M | (m) | 5.04× |
| 2025-12-31 | $459.35M | $103.88M | $155.46M | $294.42M | $9.47M | (m) | 4.42× |
| 2025-09-30 | $522.09M | $93.73M | $193.39M | $317.65M | $11.05M | (m) | 5.57× |
| 2025-06-30 | $471.00M | $95.50M | $156.17M | $303.48M | $11.35M | (m) | 4.93× |
| 2025-03-31 | $514.25M | $112.59M | $126.88M | $376.87M | $10.50M | (m) | 4.57× |
| 2024-12-31 | $610.03M | $110.85M | $189.18M | $412.33M | $8.52M | (m) | 5.50× |
| 2024-09-30 | $666.97M | $105.68M | $120.50M | $537.62M | $8.85M | (m) | 6.31× |
| 2024-06-30 | $703.40M | $105.09M | $130.85M | $560.22M | $12.33M | (m) | 6.69× |
| 2024-03-31 | $827.72M | $97.91M | $171.98M | $619.32M | $36.43M | (m) | 8.45× |
| 2023-12-31 | $948.68M | $115.21M | $226.75M | $685.48M | $36.46M | (m) | 8.23× |
| 2023-09-30 | $861.28M | $91.95M | $168.03M | $686.76M | $6.49M | (m) | 9.37× |
| 2023-06-30 | $913.13M | $99.85M | $171.81M | $736.27M | $5.06M | (m) | 9.14× |
| 2023-03-31 | $938.45M | $103.38M | $294.15M | $639.39M | $4.91M | (m) | 9.08× |
| 2022-12-31 | $1.20B | $126.55M | $523.51M | $669.12M | $3.77M | (m) | 9.45× |
| 2022-09-30 | $832.22M | $131.13M | $141.19M | $687.00M | $4.02M | (m) | 6.35× |
| 2022-06-30 | $877.13M | $123.76M | $147.78M | $726.49M | $2.85M | (m) | 7.09× |
| 2022-03-31 | $857.05M | $126.11M | $133.38M | $721.87M | $1.80M | (m) | 6.80× |
| 2021-12-31 | $750.72M | $125.83M | $123.41M | $625.28M | $2.03M | (m) | 5.97× |
| 2021-09-30 | $800.76M | $97.57M | $334.74M | $463.53M | $2.49M | (m) | 8.21× |
| 2021-06-30 | $531.01M | $73.96M | $129.88M | $399.14M | $1.99M | (m) | 7.18× |
| 2021-03-31 | $585.02M | $60.70M | $141.54M | $442.52M | $953.00K | (m) | 9.64× |
| 2020-12-31 | $599.50M | $64.25M | $160.02M | $437.35M | $2.13M | (m) | 9.33× |
| 2020-09-30 | $409.16M | $55.87M | $179.75M | $228.20M | $1.22M | (m) | 7.32× |
| 2020-06-30 | $440.67M | $59.14M | $361.69M | $75.12M | $3.86M | (m) | 7.45× |
| 2020-03-31 | $263.63M | $35.30M | $80.99M | $169.27M | $13.37M | (m) | 7.47× |
| 2019-12-31 | $284.35M | $35.63M | $57.23M | $222.50M | $4.62M | (m) | 7.98× |
| 2019-09-30 | $289.52M | $37.52M | $38.44M | $247.48M | $3.60M | (m) | 7.72× |
| 2019-06-30 | $275.29M | $38.46M | $49.14M | $221.96M | $4.19M | (m) | 7.16× |
| 2019-03-31 | (m) | $39.23M | $47.10M | (m) | $3.59M | (m) | (m) |
| 2018-12-31 | (m) | $40.57M | $58.86M | (m) | $7.55M | (m) | (m) |
| 2018-09-30 | (m) | $25.91M | $293.25M | (m) | $2.81M | (m) | (m) |
| 2018-06-30 | (m) | $25.17M | $305.54M | (m) | $8.61M | (m) | (m) |
| 2018-03-31 | (m) | $25.58M | $327.78M | (m) | $7.47M | (m) | (m) |
| 2017-12-31 | (m) | $31.36M | $340.68M | (m) | $10.47M | (m) | (m) |
| 2017-09-30 | (m) | $25.79M | $222.26M | (m) | $4.49M | (m) | (m) |
| 2017-06-30 | (m) | $26.37M | $241.05M | (m) | $2.76M | (m) | (m) |
| 2017-03-31 | (m) | $24.91M | $257.55M | (m) | $2.44M | (m) | (m) |
| 2016-12-31 | (m) | $30.73M | $273.06M | (m) | $6.45M | (m) | (m) |
| 2016-09-30 | (m) | $22.63M | $290.62M | (m) | $1.11M | (m) | (m) |
| 2016-06-30 | (m) | $21.62M | $300.69M | (m) | $1.00M | (m) | (m) |
| 2016-03-31 | (m) | $10.96M | $64.19M | (m) | $1.00M | (m) | (m) |
| 2015-12-31 | (m) | $10.70M | $75.82M | (m) | $1.00M | (m) | (m) |
| 2015-09-30 | (m) | (m) | $82.61M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $19.77M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $18.48M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $9.85M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |